Deletion of the survival motor neuron (SMN) gene is the most common molecular basis of spinal muscular atrophy (SMA), which is a common autosomal recessive neuromuscular disease characterized by degeneration of the anterior horn cells of the spinal cord. The carrier rate of SMA varies from 2% to 3% in different populations. [1] [2] [3] SMA is generally divided into three groups, based on age at onset and disease severity: 1. Type I (infantile type, OMIM# 253300). These patients usually develop muscle weakness at birth or before 6 months of age and die of respiratory failure within 2 years. 2. Type II (OMIM# 253550). The onset is usually 18 months after birth. These patients can sit, but are never able to walk by themselves and can survive beyond 4 years of age. 3. Type III (OMIM# 253400). These patients develop symptoms after 18 months and are able to walk, but often become wheelchair bound during youth or adulthood. 4 Two highly homologous SMN genes (SMN1 and SMN2) are located in the highly duplicated region of 5q13. SMN consists of nine exons (1, 2a, 2b, 3-8) , with the stop codon present near the end of exon 7. The coding sequence of SMN2 differs from that of SMN1 by a single nucleotide (840CϾT) in exon 7. In exon 8, SMN2 differs from SMN1 by another single nucleotide (GϾA). Most of the SMN protein in a normal subject is derived from SMN1, and only a very small amount of SMN protein is derived from SMN2. Gene deletion or conversion is relatively common between SMN1 and SMN2, due to the sequence homology of the two SMN genes and their flanking regions. More than 95% of the SMA alleles of all three types of patients are due to deletion or gene conversion of SMN1, and about 5% of the diseased alleles are due to intragenic point mutations of SMN1. In patients with a total deletion of both copies of SMN1, the presence of SMN2 genes alleviates the disease severity. Compared with Type I patients, a higher proportion of Type III patients have four copies of SMN2. 5, 6 Many different methods for determining the copy number of SMN1 have been reported, including single-strand conformation polymorphism (SSCP), polymerase chain reaction (PCR)-restriction-fragment length polymorphism (RFLP), denatured high-performance liquid chromatography (DHPLC), and real-time quantitative PCR. [7] [8] [9] [10] [11] [12] [13] [14] In 2002, Schouten et al. 15 reported a novel method for the relative quantification of up to 40 nucleic acid sequences in a single-tube, multiplex ligation-dependent probe amplification (MLPA). This method has been applied to detect deletion and duplication in many conditions, including trisomy syndromes, breast cancer, colon cancer, and Duchenne muscular dystrophy. 16 -22 Two reports have been published addressing SMA with MLPA. 23, 24 In this study, we used MLPA to analyze the copy number of the SMN1 and SMN2 genes in Taiwanese subjects and compared the MLPA results with those of DHPLC in 20 subjects.
MATERIALS AND METHODS
Three groups of subjects were recruited for this series. Group 1 consisted of 310 unrelated subjects without a history of muscular atrophy; Group 2 was composed of 63 subjects with 18 SMA patients and 45 carriers; and Group 3 comprised 20 subjects who had been screened with DHPLC at other laboratories, with 19 being told they were carriers of SMA. Informed consent to participate in the study was obtained from each subject. Among the 45 carriers in Group 2, 29 were parents of the patients, and 16 were ascertained through DHPLC or by repeated MLPA analysis.
DNA was extracted, using standard methods, from the peripheral blood of each subject. A spectrophotometer was used to determine the concentration of the DNA samples. Using a commercially available Salsa MLPA kit P021 (MRC-Holland), we genotyped the copy number of SMN1 and SMN2 in each subject. The kit contained 16 probes in the 5q13 region and another 22 control probes from other chromosomes. Details of probe sequences and gene loci are shown on the Web site (http://www.mrc-holland.com).
Among the 16 probes from the 5q13 region, eight were used to detect the copy numbers of SMN1 and/or SMN2: the SMN1-D01 probe for the copy number of SMN1 exon 7; the SMN2-D01 probe for the copy number of SMN2 exon 7; the SMN1-D07 probe for the copy number of SMN1 exon 8; the SMN2-D07 probe for the copy number of SMN2 exon 8; and four probes, SMN1/2-D03, -D04, -D05, and -D06, for the copy number detection of exons 8, 1, 4, 6, respectively, for both SMN1 and SMN2.
MLPA analysis was performed according to the manufacturer's protocol (MRC Holland). Briefly, 50 -500 ng of DNA was denatured (98°C, 5 minutes) and hybridized with the probe set overnight at 60°C, using the SALSA probe mix. Ligation was performed with ligase-65 enzyme at 54°C for 15 minutes. The reactions were inactivated by incubation at 98°C for 15 minutes. PCR was performed with the specific SALSA FAM PCR primers for 35 cycles (95°C for 30 seconds; 60°C for 30 seconds; 72°C for 1 minute). The PCR products were analyzed in a capillary DNA sequencer (ABI PRISM 3100, Applied Biosystems, Darmstadt, Germany) with Genescan 3.7 Software (Applied Biosystems). One microliter of the PCR product was mixed with 0.5 L of Genescan-Rox 500 size standard and 8.5 L of deionized formamide. The run time was 60 minutes using a 36-cm capillary at 60°C.
Data analysis
According to the length (bp, base pairs) of the PCR products, the 38 probes, with the 16 5q13 probes shown in boldface, were divided into four groups, namely group A (94 -211 bp) (10 probes: 2q14, 12q14, CDH6-D01, 3q12, 17p11.2, 18q21.2, GTF2H2-D02, 7q21, RAD17-D02, and 10p15.1); group B (220 -310 bp) (11 probes: GTF2H2-D03, 11q13, BIRC1-D02, 21q11, 18p11, SMN1-D01, SMN2-D01, 3q21, SMN1-D07, SMN2-D07, and 13q34); group C (319 -391 bp) (nine probes: 8q24, GTF2H2-D01, 21q21.3, BIRC1-D01, 2p24, SMN1/2-D03, 8p11.2, SMN1/2-D04, and 3p26); and group D (400 -463 bp) (eight probes: SMN1/2-D05, 2p14, SMN1/2-D06, 8q24.11, 17q12, 13q34, N-cadherin-like-D01, and 12q24.13) (Fig. 1) .
Data analysis was performed as reported by Gerdes et al. 25 (the software is free and can be downloaded at www.chromosomelab.dk). Briefly, after automatic peak recognition and normalization, a probe ratio of each peak was computed by dividing the area by a corresponding reference mean peak area. The normalization was done separately for Groups A, B, C, and D, but for the SMA analysis, the method was modified to base normalization on the control peak areas only, e.g., each probe area of Group B was normalized by dividing it by the mean of the control probe areas within Group B. Forty-eight goodquality 2:2 samples, each having an SD of the 21 control peak ratios at Ͻ0.1, were used as a reference group to construct the mean peak area of each probe (the very first synthetic control probe at 94 bp was not used for this extra quality check).
For each sample, the copy number of the SMN genes was determined on the basis of the eight SMN probe ratios. If the ratios of SMN1-D01, SMN2-D01, SMN1-D07 and SMN2-D07 were between 0.75 and 1.25 and the mean ratio of four SMN1 ϩ 2 probes (SMN1/2-D03, SMN1/2-D04, SMN1/2-D05, and SMN1/2-D06) was between 0.875 and 1.125, the tested sample was interpreted to have 2:2. If the ratios of SMN1-D01 and SMN1-D07 were between 0.75 and 1.25, the ratios of SMN2-D01 and SMN2-D07 were between 0.25 and 0.75 and the mean ratio of the four SMN1 ϩ 2 probe was between 0.625 and 0.875, the tested sample was interpreted to have 2:1. If the ratios of SMN1-D01, SMN2-D01, SMN1-D07, and SMN2-D07 were between 0.25 and 0.75 and the mean ratio of the four SMN1 ϩ 2 probes between 0.375 and 0.625, the tested sample was interpreted to have 1:1 (an SMA carrier). Other combinations of SMN1 and SMN2 were deduced in a similar way. The combined copy number of SMN1 and SMN2 genes deduced from SMN1-D01, SMN2-D01, SMN1-D07, and SMN2-D07 was the same as that deduced from SMN1 ϩ 2 probes, otherwise, the reaction should be repeated. For the carriers ascertained through DHPLC and/or MLPA, MLPA analysis was performed at least twice, and consistent results was obtained before the carrier status was established.
RESULTS
Figures 2 to 10 show the electrophoreograms of the various combinations of SMN1 and SMN2. For the 1:1 (Fig. 3 ) and 2:2 ( Fig. 8 ) samples, the exon 7 peak in SMN2 was slightly higher than that in SMN1, whereas the exon 8 peaks were similar in SMN1 and SMN2. For the 2:0 samples (Fig. 6 ), a small signal was noted at the SMN2 exon 7 site and no signal was present at the SMN2 exon 8 site, whereas for the 0:3 samples (Fig. 2) , as expected, no signals were present at both the SMN1 exon 7 and 8 sites. The presence of the SMN1 exon 7 sequence seemed to contribute to a portion of the exon 7 signal of SMN2.
By comparing the peak ratios of the tested sample against the reference group, we could obtain the copy numbers of the SMN1, SMN2, and neighboring genes. Although we set a Ϯ0.25 ratio range to get the copy number for SMN1 exons 7and 8 and SMN2 exons 7 and 8 and set a Ϯ0.125 mean ratio range to get the copy number for SMN1 ϩ SMN2, the actual ratio means for the 21 genotypes from Groups 1 and 2 were clear-cut with small SDs, usually Ͻ10% of the mean (Table 1) . For a very few cases having a slight discrepancy between a 
Table 1
The mean Ϯ SD of the ratios of SMN exons in various combinations of SMN1 and SMN2 genes in subjects from Groups 1 and 2
Exon 7 copies
Exon 8 copies n
Exon 7 SMN1

Exon 7 SMN2
Exon 8 SMN1 found copy number ratio and the copy number for SMN1 ϩ SMN2, the copy number for the ratio was set to correspond to the SMN1 ϩ SMN2 copy number. Among the 16 different genotypes found in Group 1, the most common genotype was 2:2 (52.90%), followed by 2:1 (30.32%). Six (1.94%) subjects were found to be carriers of SMA. Eight subjects were noted to have one copy of a hybrid gene of SMN1 and SMN2 (Table 2) . In Group 2, all 18 SMA patients had a total deletion of their SMN1 genes: seven patients with 0:2, six with 0:3, and five with 0:4. Among the 45 carriers, 9 had a 1:1, 27 had a 1:2, 8 had a 1:3, and 1 had a 1:4 genotype ( Table 1) . Eleven patients and 20 carriers from Groups 1 and 2 had a deletion extending to the SMN1 upstream genes of BIRC1 and GTF2H2. All the seven 0:2 patients had at least one allele with the deletion extending beyond BIRC1 exon 5 (about 58 kb upstream to the SMN1 gene) and all the 0:4 patients did not have the deletion extending to the BIRC1 exon 5 (Table 3) . Among the seven patients with 0:2, six had Type I disease and one had Type II disease. Of the six patients with 0:3, five had Type II disease and one had Type I disease. All the five patients with 0:4 had Type III disease.
In Group 3, of the 20 subjects who had undergone DHPLC before to determine the status of their SMN genes, 14 had the same results with both DHPLC and MLPA; however, the other six had discrepant results. Three subjects who had been previously told they were carriers of SMA turned out to be noncarriers by MLPA (Table 4) .
Sixteen genotypes were found in Group 1 subjects (Table 1) , and five genotypes (0:2, 0:3, 0:4, 1:1, and 1:4) were found in Group 2, yielding a total of 21 genotypes detected in this series.
DISCUSSION
Copy number analysis of the SMN1 gene is important in carrier screening and prenatal diagnosis. 1,2,9,26,27 Many methods have been developed for this purpose. [7] [8] [9] 12, 13 Most of them recognize the only nucleotide difference in exon 7 between SMN1 and SMN2. SSCP is a simple method, but its sensitivity is not high. 14 PCR-RFLP is now commonly used in clinical Table 2 The distribution of SMN1:SMN2 genes in 310 subjects in group 1
SMN1:SMN2 ratio
No. of subjects Ratio (%) practice. 7 Although these methods can detect most cases of homozygous deletion of SMN1 genes, they cannot always offer a clear-cut distinction between a deletion SMA carrier and a noncarrier. Single-tube MLPA as reported here uses a single pair of PCR primers to simultaneously amplify up to 38 different DNA sequences. 15 This method detected the unique sequences of exons 7 and 8 of SMN1, exons 7 and 8 of SMN2, and the common sequences of exons 1, 4, 6, and 8 of both SMN1 and SMN2 in a single reaction. In addition, nine loci in the flanking regions of SMN genes and 22 genomic control sequences were studied in the same tube. Therefore, many internal and external controls were analyzed under the same conditions for better quality control and data confirmation. The performance of genomic controls could indicate the quality of extracted DNA, the quantity of the input DNA, and the efficiency of DNA ligation and amplification. A good-quality reaction had an SD Ͻ0.1 of the peak ratios of the 21 control probes. Data not from a good-quality reaction should be interpreted with extra caution or the whole process should be repeated, starting from blood sample collection, to obtain a correct classification. The copy number of SMN1 and SMN2 determined from the unique sequences of exons 7 and 8 should be compatible with that determined from the common sequences of exons 1, 4, 6, and 8 of both SMN1 and SMN2. In addition, we were able to compare the copy number of exon 7 of SMN1 and SMN2 with that of exon 8 of SMN1 and SMN2. Eight subjects in Group 1 were thus interpreted to have a hybrid SMN gene (Table 1) .
Loci flanking the SMN genes could confirm deletion in the SMN genes and help delineate the extent of the deletion. Patients with a more extensive deletion involving BIRC1 and GTF2H2 seemed to have a more severe phenotype. Twenty of the 51 SMA carriers had the deletion extending at least 58 kb upstream of the SMN1 gene (Table 3) . A higher copy number of the SMN2 also had an ameliorating effect on the severity of SMA. 5, 6 Three of the 19 subjects in Group 3 (Table 4 ) who had been told they were SMA carriers using DHPLC turned out to be noncarriers by MLPA. Two subjects had 2:3 and one had 2:4 SMN genes by MLPA. The presence of five copies and six copies of SMN genes were confirmed by copy number analysis of the SMN1/SMN2 probe study. MLPA analysis in these subjects was performed at least twice, and consistent results were obtained. Misclassification of a noncarrier as an SMA carrier may cause undue anxiety for the subject. In another two subjects, the copy number of SMN2 by DHPLC was different from that by MLPA (Table 4) . Although the determination of the SMN2 copy number is less important, this misclassification may be the tip of an iceberg. Currently all the DHPLC screenings for the SMN genes in Taiwan have been performed according to the protocol reported by Su et al. 13 They use a two-step method: (1) The first step of heteroduplex analysis only studies the ratio of SMN1/ SMN2 to detect the SMA carriers with a ratio other than 1. (2) The second step is a multiplex competitive PCR to calculate the total copy numbers of SMN1 ϩ SMN2 to distinguish the SMA carriers with 1:1 from the normal subjects with 2:2. In the second step, they use two control probes, CYBB (OMIM#306400, X-linked) and KRIT1 (OMIN#604214, chromosome 7q), to control for the total copy number of SMN genes. All the DHPLC results in this report seemed to have been screened with only the first-step method; therefore, 1:2 and 2:3 would have been difficult to distinguish. We believe that if the second-step procedure had been undertaken, these misclassifications would have been avoided. With MLPA, many control probes, both in the SMN region and other chromosomes, were used for total copy number reference for SMN gene or for system quality control. Copy number analysis of SMN genes with MLPA would be better and more efficient than the two-step DHPLC. 13 Detailed analysis to pinpoint the underlying causes is needed to avert misclassification of the copy number of the SMN1 gene. Although DHPLC has been successfully used in SMA carrier screening, the techniques may go wrong in inexperienced hands. The discrepancies in Group 3 may require an independent assay to clarify the status of SMN genes; however, we believe that it was less likely that MLPA results were wrong.
About 5% of the diseased SMA alleles are caused by point mutations in the coding or splicing junction region of the SMN1 gene. 5 MLPA SMN copy number analysis cannot detect these intragenic mutations. Strategies to identify these subtle mutations are needed for a complete detection of all SMA defects. 28 As demonstrated in other diseases, MLPA is a simple and effective method to determine the copy number of SMN1 and SMN2 and can play an important role in the diagnosis of patients and the mass screening of SMA carriers.
